Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a ABT-981 in knee osteoarthritis
NL-OMON41808Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of lutikizumab in knee osteoarthritis (OA) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Change in osteoarthritis knee pain at Week 16 and Synovitis/effusion volume at Week 26. Started Oct 2015; status: active, not recruiting.
02
Drugs
lutikizumab
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON41808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41808.